Tag: Vaxxas

Vaxxas, a clinical-stage biotechnology company known for its innovative high-density microarray patch (HD-MAP) vaccination platform, has secured a worldwide license from the United States National Institutes of Health (NIH) for a next-generation vaccine antigen aimed at combating Respiratory Syncytial Virus (RSV). 

Biotechnology company Vaxxas has completed work on its new needle-free vaccine technology manufacturing facility in Northshore Hamilton. 

Australia biotechnology company Vaxxas said it achieved positive interim results from a Phase I human clinical trial with the first needle-free COVID-19 vaccine candidate. 

Two projects involving medical and scientific researchers from the University of Sydney have secured government funding through the Cooperative Research Centres Projects’ (CRC-P) latest round. 

Vaxxas has commenced the Phase I clinical trial of the first needle-free inactivated seasonal influenza vaccine quadrivalent (IIV4) candidate via its proprietary high-density microarray patch (HD-MAP) technology.

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, has announced it has completed a financing round which raised US$23 million (A$34 million) in new funds.

Australian biotechnology company Vaxxas has begun the Phase I clinical trial of the first needle-free COVID-19 vaccine candidate. 

Media Release by Vaxxas Vaxxas will receive an AU$8.2 million second-round grant as part of the Commonwealth Government’s Modern Manufacturing Initiative (MMI) to support the...

Vaxxas, a Queensland biotechnology business, has begun construction on a new facility in Northshore Hamilton, Brisbane to develop and manufacture its needle-free vaccination technology. The...

Five medical product manufacturers will share over $36 million in grants through round 1 of the Modern Manufacturing Initiative (MMI) Translation and Integration streams. The...